Display Settings:

Format

Send to:

Choose Destination
    J Hematol Oncol. 2008 Oct 17;1:18.

    Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.

    Source

    The Ohio State University Medical Center, 395 W, 12th Avenue, Columbus, OH 43210, USA. brian.so@osumc.edu

    Abstract

    Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.

    PMID:
    18928548
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2575202
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 2
    Figure 1

      Supplemental Content

      Click here to read Click here to read

      Chemical compound information

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk